Position in NBIX
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$565,282
+$138,182 QoQ
Shares Held
3,354
+3.5% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#458
of 768 holders
Holding Since
Dec 2024
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Ballentine Partners, LLC holds $5,578,380 across 9 Drug Manufacturers - Specialty & Generic names. NBIX ranks #4 (10.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RDY |
Dr Reddys Laboratories Ltd
|
107,479 | $1,557,370 | |
| 2 | LQDA |
Liquidia Corp
|
12,163 | $969,755 | |
| 3 | ZTS |
Zoetis Inc.
|
9,842 | $707,245 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
This page
|
3,354 | $565,282 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
30,095 | $482,421 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
11,392 | $385,959 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
608 | $329,431 | |
| 8 | HLN |
Haleon plc
|
33,797 | $315,325 |
All Filings in NBIX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $565,282 | 3,354 | Shares | Other | 2026-07-17 | |
| 2026-03-31 | $427,100 | 3,242 | Shares | Sole | 2026-05-14 | |
| 2024-12-31 | $228,637 | 1,675 | Shares | Other | 2025-01-16 | |
| No filing history on record for this holder in this stock. | ||||||